STATES 2.0 Act
Summary
What This Bill Does
The bill creates congressional findings on state cannabis policy diversity, illicit market dominance (75%), excessive taxation driving illegal sales, and need for federal regulatory framework, creates sense of Congress that FDA should support tribal self-determination and treaty rights regarding marijuana regulation, and amends Controlled Substances Act to exempt state-legal and tribal-legal marijuana from federal prohibition, enable interstate transport between legal states, remove marijuana from federal schedule for compliant. It relies on exemptions, definition changes, product standards, and compliance mandates. The main policy areas are Agriculture, Criminal Justice, Healthcare, and Transportation.
Who Benefits and How
State-legal cannabis businesses could face fewer barriers, Federally recognized Indian tribes could face fewer barriers, and Interstate cannabis transport operators could gain revenue opportunities.
Who Bears the Burden and How
Federal drug enforcement (DEA) could lose revenue opportunities, Cannabis product manufacturers would take on compliance duties, and FDA would take on compliance duties.
Key Provisions
- Creates congressional findings on state cannabis policy diversity, illicit market dominance (75%), excessive taxation driving illegal sales, and need for federal regulatory framework.
- Creates sense of Congress that FDA should support tribal self-determination and treaty rights regarding marijuana regulation.
- Amends Controlled Substances Act to exempt state-legal and tribal-legal marijuana from federal prohibition, enable interstate transport between legal states, remove marijuana from federal schedule for compliant...
- Exempts new Section 710 of CSA providing detailed rules: state compliance exemption, tribal compliance exemption, interstate transportation protections, preserved federal offenses (distribution to minors, transportation...
- Requires FDA regulatory framework for marijuana products: drugs treated as drugs, food/dietary supplements regulated like alcohol-containing food, cosmetics treated as cosmetics, other products require new regulation...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates congressional findings on state cannabis policy diversity, illicit market dominance (75%), excessive taxation driving illegal sales, and need for federal regulatory framework, creates sense of Congress that FDA should support tribal self-determination and treaty rights regarding marijuana regulation, and amends Controlled Substances Act to exempt state-legal and tribal-legal marijuana from federal prohibition, enable interstate transport between legal states, remove marijuana from federal schedule for compliant.
Key Policy Areas
Agriculture, Criminal Justice, Healthcare, Transportation
Primary Purpose
The bill creates congressional findings on state cannabis policy diversity, illicit market dominance (75%), excessive taxation driving illegal sales, and need for federal regulatory framework, creates sense of Congress that FDA should support tribal self-determination and treaty rights regarding marijuana regulation, and amends Controlled Substances Act to exempt state-legal and tribal-legal marijuana from federal prohibition, enable interstate transport between legal states, remove marijuana from federal schedule for compliant.
Policy Domains
Section 4 - Rule Regarding Application to Marijuana
Identified Gains
- State-legal cannabis businesses
- Federally recognized Indian tribes
- Interstate cannabis transport operators
- Cannabis consumers in legal states
- Cannabis consumers
Identified Costs
- Federal drug enforcement (DEA)
- Cannabis product manufacturers
- FDA
- Pharmaceutical and tobacco companies
- National Highway Traffic Safety Administration
Sponsors
Legislative Progress
In CommitteeMr. Joyce of Ohio (for himself, Mr. Miller of Ohio, …
Referred to the Committee on Energy and Commerce, and in …
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Cannabis consumers, Cannabis consumers in legal states, Cannabis product manufacturers
Positive-direction: Cannabis consumers, Cannabis consumers in legal states, Interstate cannabis transport operators, State-legal cannabis businesses, State-legal cannabis industry
Negative-direction: Cannabis product manufacturers
FDA, Federal drug enforcement, National Highway Traffic Safety Administration
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_attorney_general"
- → Attorney General
- "the_secretary"
- → Secretary of Health and Human Services
- "the_commissioner"
- → Commissioner of Food and Drugs
Key Definitions
Terms defined in this bill
As defined in section 102 of the Federally Recognized Indian Tribe List Act of 1994
Any product made or derived from marijuana intended for human or animal consumption, including any component of marijuana
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology